Ravindra Majeti

The adhesion molecule esam1 is a novel hematopoietic stem cell marker.

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Metastatic cancer stem cells: an opportunity for improving cancer treatment?

Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.

Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye.

Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments.

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Surprise! HSC are aberrant in chronic lymphocytic leukemia.

Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Programmed cell removal: a new obstacle in the road to developing cancer.

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications.

Clonal evolution of acute leukemia genomes.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould.

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.

Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.

Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.

Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.

Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands.

Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.

Reply to Fišer et al.: Myeloid reprogramming of Ph+ B-ALL: A potential therapeutic strategy.

Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.

Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation.

SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Burning Fat Fuels Leukemic Stem Cell Heterogeneity.

Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.

The role of mutations in the cohesin complex in acute myeloid leukemia.

CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.

Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML.

Biology and relevance of human acute myeloid leukemia stem cells.

Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.

Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.

Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation.

Targeting Cancer Stemness in the Clinic: From Hype to Hope.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Induced pluripotent stem cell modeling of malignant hematopoiesis.

Data mining for mutation-specific targets in acute myeloid leukemia.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML.

Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA.

Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.

The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.

Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.

Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion.

A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.

IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.

Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.

Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.

CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products.

Targeting LSCs: Peeling Back the Curtain on the Metabolic Complexities of AML.

The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells.

Clonal Hematopoiesis: From Mechanisms to Clinical Intervention.

Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity.

Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.

CytofIn enables integrated analysis of public mass cytometry datasets using generalized anchors.

The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia.

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.

Single-cell genomics in AML: extending the frontiers of AML research.

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.

Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy.

An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).

MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia.

RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.

Convergent Epigenetic Evolution Drives Relapse in Acute Myeloid Leukemia.